Mirati Therapeutics, Inc.
MRTX
Hisse Senetlerindeki Sıralama
#4928
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Hisse Fiyatı
$58.70
Son senkronizasyon: 2024-01-23
Piyasa Değeri
$2.98B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Mirati Therapeutics, Inc. (MRTX)
Kategori
Healthcare
Mirati Therapeutics, Inc. (MRTX) için temettü verimi geçmişi
Mirati Therapeutics, Inc. (hisse sembolü: MRTX) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
Mirati Therapeutics, Inc. (MRTX) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
| Yıl | Temettü Verimi | Değiştir |
|---|---|---|
| Sağlanan tarihler için yeterli veri yok. | ||
Benzer şirketler veya rakiplerin temettü verimi (TTM)
| Şirket | Temettü Verimi | Ülke |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
